- Home
- FREY vs XOMA Comparison
FREY vs XOMA Comparison
Compare FREY & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FREY
- XOMA
- Stock Information
- Founded
- FREY 2018
- XOMA 1981
- Country
- FREY Luxembourg
- XOMA United States
- Employees
- FREY N/A
- XOMA N/A
- Industry
- FREY Industrial Machinery/Components
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- FREY Miscellaneous
- XOMA Health Care
- Exchange
- FREY Nasdaq
- XOMA Nasdaq
- Market Cap
- FREY 154.4M
- XOMA 320.8M
- IPO Year
- FREY N/A
- XOMA N/A
- Fundamental
- Price
- FREY $1.09
- XOMA $28.46
- Analyst Decision
- FREY Hold
- XOMA Strong Buy
- Analyst Count
- FREY 4
- XOMA 2
- Target Price
- FREY $1.95
- XOMA $78.50
- AVG Volume (30 Days)
- FREY 1.1M
- XOMA 21.5K
- Earning Date
- FREY 11-07-2024
- XOMA 11-05-2024
- Dividend Yield
- FREY N/A
- XOMA N/A
- EPS Growth
- FREY N/A
- XOMA N/A
- EPS
- FREY N/A
- XOMA N/A
- Revenue
- FREY N/A
- XOMA $15,239,000.00
- Revenue This Year
- FREY N/A
- XOMA $456.45
- Revenue Next Year
- FREY $414.23
- XOMA $29.84
- P/E Ratio
- FREY N/A
- XOMA N/A
- Revenue Growth
- FREY N/A
- XOMA 277.95
- 52 Week Low
- FREY $0.91
- XOMA $14.27
- 52 Week High
- FREY $3.73
- XOMA $30.50
- Technical
- Relative Strength Index (RSI)
- FREY 53.92
- XOMA 53.55
- Support Level
- FREY $1.01
- XOMA $28.66
- Resistance Level
- FREY $1.04
- XOMA $30.50
- Average True Range (ATR)
- FREY 0.05
- XOMA 1.07
- MACD
- FREY 0.02
- XOMA 0.21
- Stochastic Oscillator
- FREY 100.00
- XOMA 55.56
About FREY FREYR Battery Inc.
FREYR Battery Inc is an emerging producer of clean battery solutions for the planet. It designs and manufactures high-density and cost-competitive lithium-ion batteries with a reduced carbon footprint for the markets for electric mobility, stationary energy storage, and marine and aviation applications.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. When XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes.